According to IMARC Group’s latest report, titled “Multiple Sclerosis Therapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, the global multiple sclerosis therapies market exhibited moderate growth during 2015-2020. Multiple sclerosis (MS) therapies involve the administration of injectable, infused and oral medicines, antidepressants, muscle relaxants, and physical therapy. They aid in slowing the progression of the disease and managing associated symptoms. Apart from this, they also help in controlling the heart rate and blood pressure and minimizing the frequency of relapses among patients.
Request for a PDF sample of this report:https://www.imarcgroup.com/multiple-sclerosis-therapies-market/requestsample
At present, the increasing prevalence of relapsing-remitting and secondary progressive MS across the globe represents one of the primary factors driving the market. Besides this, governing agencies of numerous countries are launching campaigns to generate awareness about the available treatments. This, along with the technological advancements, such as the introduction of innovative immunomodulators, monoclonal bodies, interferons, and immunosuppressants for the effective treatment of MS, is creating a favorable market outlook. Other factors, including considerable improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are anticipated to stimulate the growth of the market. Looking forward, IMARC Group expects the global multiple sclerosis therapies market to grow at a CAGR of around 5% during the forecast period (2021-2026).
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviors of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
Competitive Landscape with Key Players:
- Abbvie Inc.
- Bayer Aktiengesellschaft
- Biogen Inc.
- Bristol-Myers Squibb Company
- Hoffmann-La Roche AG (Roche Holding AG)
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
Breakup by Drug:
Breakup by Drug Type:
- Biologic Drugs
- Small Molecule Drugs
Breakup by Route of Administration:
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Breakup by Region:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Others)
Ask Analyst for Customization and Explore full report with TOC & List of Figures: https://bit.ly/2SGXQL7
We are updating our reports, If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.
Key highlights of the report:
- Market Performance (2015-2020)
- Market Outlook (2021-2026)
- Market Trends
- Market Drivers and Success Factors
- The Impact of COVID-19 on the Global Market
- Value Chain Analysis
- Structure of the Global Market
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800